
Zdravstvena informatika - Identifikacija zdravil - Elementi in zgradba podatkov za enotno identifikacijo in izmenjavo predpisanih informacij o zdravilih (ISO/DIS 11615:2025)

Health informatics - Identification of medicinal products - Data elements and structures for the unique identification and exchange of regulated medicinal product information (ISO/DIS 11615:2025)

Medizinische Informatik - Identifikation von Arzneimitteln - Datenelemente und Strukturen zur eindeutigen Identifikation und zum Austausch von vorgeschriebenen Arzneimittelinformationen (ISO/DIS 11615:2025)

Informatique de santé - Identification des médicaments - Éléments de données et structures pour l'identification unique et l'échange d'informations sur les médicaments contrôlés (ISO/DIS 11615:2025)

<https://standards.iteh.ai/catalog/standards/sist/4d82d63e-3dfe-41ed-820a-14cf0fdf63e2/osist-pren-iso-11615-2025>

Ta slovenski standard je istoveten z: prEN ISO 11615

ICS:

11.120.10	Zdravila	Medicaments
35.240.80	Uporabniške rešitve IT v zdravstveni tehniki	IT applications in health care technology

oSIST prEN ISO 11615:2025

en,fr,de



DRAFT International Standard

ISO/DIS 11615

Health informatics — Identification of medicinal products — Data elements and structures for the unique identification and exchange of regulated medicinal product information

*Informatique de santé — Identification des médicaments —
Éléments de données et structures pour l'identification unique et
l'échange d'informations sur les médicaments contrôlés*

ICS: 35.240.80

ISO/TC 215

Secretariat: **ANSI**

Voting begins on:
2025-09-19

Voting terminates on:
2025-12-12

<https://standards.iteh.ai/catalog/standards/sist/4d82d63e-3dfe-41ed-820a-14cf0dfd63e2/osist-pren-iso-11615-2025>

This document has not been edited by the ISO Central Secretariat.

ISO/CEN PARALLEL PROCESSING

Reference number
ISO/DIS 11615:2025(en)

THIS DOCUMENT IS A DRAFT CIRCULATED FOR COMMENTS AND APPROVAL. IT IS THEREFORE SUBJECT TO CHANGE AND MAY NOT BE REFERRED TO AS AN INTERNATIONAL STANDARD UNTIL PUBLISHED AS SUCH.

IN ADDITION TO THEIR EVALUATION AS BEING ACCEPTABLE FOR INDUSTRIAL, TECHNOLOGICAL, COMMERCIAL AND USER PURPOSES, DRAFT INTERNATIONAL STANDARDS MAY ON OCCASION HAVE TO BE CONSIDERED IN THE LIGHT OF THEIR POTENTIAL TO BECOME STANDARDS TO WHICH REFERENCE MAY BE MADE IN NATIONAL REGULATIONS.

RECIPIENTS OF THIS DRAFT ARE INVITED TO SUBMIT, WITH THEIR COMMENTS, NOTIFICATION OF ANY RELEVANT PATENT RIGHTS OF WHICH THEY ARE AWARE AND TO PROVIDE SUPPORTING DOCUMENTATION.

© ISO 2025

ISO/DIS 11615:2025(en)

iTeh Standards (<https://standards.iteh.ai>) Document Preview

[oSIST prEN ISO 11615:2025](https://standards.iteh.ai/catalog/standards/sist/4d82d63e-3dfe-41ed-820a-14cf0fdf63e2/osist-pren-iso-11615-2025)

<https://standards.iteh.ai/catalog/standards/sist/4d82d63e-3dfe-41ed-820a-14cf0fdf63e2/osist-pren-iso-11615-2025>



COPYRIGHT PROTECTED DOCUMENT

© ISO 2025

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

ISO/DIS 11615:2025(en)

Contents

Page

Foreword	vi
Introduction	vii
1 Scope	1
2 Normative references	1
3 Terms and definitions	2
3.1 Terms and definitions	2
3.2 Abbreviated terms	12
4 Message exchange format	13
5 Conformance terminology and context as it relates to the ISO IDMP standards and corresponding IDMP technical specifications	13
6 Concepts required for the unique identification of medicinal products	13
6.1 General considerations	13
6.2 Authorised medicinal products	14
6.3 Investigational medicinal products	14
6.4 Concepts required for the unique identification of a medicinal product and the association with PhPID(s)	14
6.5 Concepts required for the unique identification of medicinal products and the association with the marketing authorisation number	15
6.6 Concepts required for the unique identification of medicinal products and the association with data carrier identifiers	15
7 Description of the information modelling principles and practices	16
7.1 General considerations	16
7.2 Conceptual overview diagrams	16
7.3 High-level diagrams	17
7.4 Detailed description diagrams	18
7.4.1 General	18
7.4.2 Relationships between classes	18
7.4.3 Attributes of classes	19
7.4.4 Generalised classes and patterns	19
7.4.5 Translation and language	19
8 Identifying characteristics for authorised Medicinal Products	19
8.1 Primary identifiers — General considerations	19
8.2 Medicinal Product Identifier (MPID)	20
8.2.1 General considerations	20
8.2.2 MPID code segments	20
8.3 Packaged Medicinal Product Identifier (PCID)	21
8.3.1 General considerations	21
8.3.2 Package description (PCID) code segment	22
8.4 Medicinal Product Batch Identifier (BAID1)	22
8.5 Medicinal Product Batch Identifier (BAID2)	22
9 Information for an authorised medicinal product	23
9.1 Authorised medicinal product — Information overview	23
9.1.1 General	23
9.1.2 Medicinal product	23
9.1.3 Medicinal product name	23
9.1.4 Header	24
9.1.5 Manufacturer or establishment (organisation)	24
9.1.6 Marketing authorisation	24
9.1.7 Packaged medicinal product	24
9.1.8 Pharmaceutical product	24
9.1.9 Ingredient	24

ISO/DIS 11615:2025(en)

9.1.10	Clinical particulars.....	24
9.2	Medicinal product.....	24
9.2.1	General.....	24
9.2.2	Detailed description of medicinal product information.....	25
9.3	Marketing authorisation.....	31
9.3.1	General.....	31
9.3.2	Detailed description of marketing authorisation information.....	32
9.4	Organisation.....	37
9.4.1	General.....	37
9.4.2	Detailed description of organisation information.....	37
9.5	Manufacturer or Establishment (organisation).....	40
9.5.1	General.....	40
9.5.2	Detailed description of manufacturer or establishment (organisation) information.....	40
9.6	Packaged medicinal product, including manufactured item and device.....	41
9.6.1	General.....	41
9.6.2	Detailed description of packaged medicinal product information.....	42
9.7	Ingredient, substance and strength.....	52
9.7.1	General.....	52
9.7.2	Detailed description of ingredients, substance and strength information.....	52
9.8	Pharmaceutical product and device.....	55
9.8.1	General.....	55
9.8.2	Detailed description of pharmaceutical product and device information.....	56
9.9	Clinical particulars.....	58
9.9.1	General.....	58
9.9.2	Detailed description for clinical particulars information.....	59
10	Identifying characteristics for investigational medicinal products.....	63
10.1	General.....	63
10.2	Primary identifiers.....	63
10.3	Investigational medicinal product identifier (IMPID).....	64
10.3.1	General considerations.....	64
10.3.2	IMPID code segments.....	64
10.4	Investigational medicinal product package identifier (IPCID).....	65
10.4.1	General provisions.....	65
10.4.2	Package description code segment.....	65
10.5	Investigational medicinal product batch identifier (BAID1).....	65
10.6	Investigational medicinal product batch identifier (BAID2).....	66
11	Information for an investigational medicinal product.....	66
11.1	General.....	66
11.2	Conceptual overview of the information for an investigational medicinal product.....	66
11.2.1	General.....	66
11.2.2	Investigational medicinal product.....	67
11.2.3	Investigational medicinal product name.....	67
11.2.4	Header.....	67
11.2.5	Manufacturer or Establishment (organisation).....	67
11.2.6	Clinical trial authorisation.....	68
11.2.7	Investigational packaged medicinal product.....	68
11.2.8	Pharmaceutical product.....	68
11.2.9	Ingredient.....	68
11.2.10	Clinical particulars.....	68
11.3	Investigational medicinal product.....	68
11.3.1	General.....	68
11.3.2	Detailed description of investigational medicinal product information.....	69
11.4	Clinical trial authorisation.....	71
11.4.1	General.....	71
11.4.2	Detailed description of clinical trial authorisation information.....	71
11.5	Manufacturer or establishment (organisation).....	73
11.6	Investigational packaged medicinal product.....	73

ISO/DIS 11615:2025(en)

11.7	Pharmaceutical product.....	73
11.7.1	General.....	73
11.7.2	Pharmaceutical product.....	74
11.7.3	Dosing and route of administration.....	74
11.8	Ingredient.....	75
11.9	Clinical particulars.....	75
11.10	PhPID sets.....	75
11.11	Device nomenclature.....	75
11.12	Device batch identifier.....	75
11.13	Physical characteristics.....	75
Annex A	(normative) Full model — Authorised medicinal products detailed diagram.....	76
Annex B	(normative) Full model — Investigational medicinal products detailed diagram.....	77
Annex C	(informative) Class name and attribute translations and synonyms for the identification of medicinal products (IDMP).....	78
Bibliography		79

iTech Standards
(<https://standards.iteh.ai>)
Document Preview

[oSIST prEN ISO 11615:2025](https://standards.iteh.ai/catalog/standards/sist/4d82d63e-3dfe-41ed-820a-14cf0fdf63e2/osist-pren-iso-11615-2025)

<https://standards.iteh.ai/catalog/standards/sist/4d82d63e-3dfe-41ed-820a-14cf0fdf63e2/osist-pren-iso-11615-2025>